Fundz

United Immunity raises ¥2.2B ($13.9M) in private equity and debt financing led by ITOCHU Corporation and others to advance UI-102 program for solid tumors and fibrotic diseases.

PRIVATESep 24, 2026

Amount Raised

$13.9 Million

Round Type

Debt Financing

TokyoBiotechnologyTherapeutics

Investors

Utec 5 Investment Limited PartnershipItochu CorporationMizuho Life Science No. 1 Investment Limited PartnershipMufg Life Science No. 2 Investment Limited PartnershipMiyako Kyoto University Innovation No. 3 Investment Limited PartnershipThe Joyo Bank, Ltd.Aozora Hybrid No. 3 Investment Limited PartnershipKuc No. 1 Investment Limited PartnershipNvcc No. 10 Investment Limited PartnershipFujita Tt Impact No. 1 Investment Limited PartnershipOno Venture Investment, Inc.Ricoh Biomedical Startup Investment Limited PartnershipSaisei Bioventures L.P.

Description

United Immunity, a Tokyo-based clinical-stage biotechnology company, raised ¥2.2B (approximately USD 13.9M) comprising ¥1.8B in private equity financing and ¥0.4B in debt financing. The funding was backed by a consortium of 13 investors including ITOCHU Corporation, Ono Venture Investment, and multiple life science investment partnerships. The company will use the proceeds to accelerate R&D of its lead program UI-102 and in vivo macrophage engineering programs targeting solid tumors and fibrotic diseases, while expanding R&D capabilities globally.

Quick answer

United Immunity raised $13.9 Million in a Debt Financing round, dated September 24, 2026. Investors: Utec 5 Investment Limited Partnership, Itochu Corporation, Mizuho Life Science No. 1 Investment Limited Partnership, Mufg Life Science No. 2 Investment Limited Partnership, Miyako Kyoto University Innovation No. 3 Investment Limited Partnership, The Joyo Bank, Ltd., Aozora Hybrid No. 3 Investment Limited Partnership and Kuc No. 1 Investment Limited Partnership. United Immunity is based in Tokyo, Tokyo, Japan.

How much did United Immunity raise?
United Immunity raised $13.9 Million in a Debt Financing round on September 24, 2026.
Who invested in United Immunity?
Utec 5 Investment Limited Partnership, Itochu Corporation, Mizuho Life Science No. 1 Investment Limited Partnership, Mufg Life Science No. 2 Investment Limited Partnership, Miyako Kyoto University Innovation No. 3 Investment Limited Partnership, The Joyo Bank, Ltd., Aozora Hybrid No. 3 Investment Limited Partnership and Kuc No. 1 Investment Limited Partnership are named as investors in this round.
What does United Immunity do?
United Immunity is a Tokyo-based clinical-stage biotechnology company developing a proprietary Myeloid Targeting Platform designed to selectively target and program macrophages and dendritic cells using pullulan-based..
Where is United Immunity based and how big is it?
United Immunity is based in Tokyo, Tokyo, Japan. Fundz records about 17 employees.
Who are the decision-makers at United Immunity?
Fundz holds 2 contacts at United Immunity, including the Chief Medical Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as United Immunity that raised within 45 days of this round, from Fundz verified event records.

  • BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
  • Anaheim Bio raised $45M (Series A) on November 5, 2026.
  • Alethio raised $90M (Series A) on November 5, 2026.
  • Emvena Therapeutics raised an undisclosed amount (Seed) on November 4, 2026.
  • MyoPax raised an undisclosed amount (Pre-Seed) on November 4, 2026.
  • Biograil raised $22M on November 4, 2026.

Who to call at United Immunity, and when

A new round usually means United Immunity is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day United Immunity raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at United Immunity, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at United Immunity. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

United Immunity

Location

Tokyo, Tokyo, Japan

About

United Immunity is a Tokyo-based clinical-stage biotechnology company developing a proprietary Myeloid Targeting Platform designed to selectively target and program macrophages and dendritic cells using pullulan-based nanoparticle technologies. The platform enables selective delivery of mRNA, siRNA, DNA, small molecules, and proteins to DC-SIGN-expressing myeloid cells for applications in cancer, fibrosis, autoimmune diseases, and infectious disease vaccines. The company is focused on accelerating R&D of its lead program UI-102 and in vivo macrophage engineering programs for treating solid tumors and fibrotic diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment United Immunity raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsKenji H., Chief Medical Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for United Immunity's next move

See what Strategic adds

United Immunity raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.